Miami Heat starters Bam Adebayo and Goran Dragic have both been ruled out for Game 3 of the NBA Finals.
Miami Heat starters Bam Adebayo and Goran Dragic have both been ruled out for Game 3 of the NBA Finals.
Japanese shares ticked up on Friday after signs of progress in U.S. stimulus talks helped Wall Street finish higher overnight, while some investors refrained from making big bets ahead of a string of earnings reports next week. Wall Street provided a strong lead as positive economic data and the prospect of more fiscal stimulus helped all three major U.S. stock indexes end higher on Thursday. The Japanese market showed little reaction to the final U.S. presidential debate ahead of the November election.
The UFC's final event of its second Fight Island stint is set following the late-night (North American time) UFC 254 weigh-in from Abu Dhabi. UFC lightweight champion Khabib Nurmagomedov was the first fighter to the scale, stripping down to hit 155 pounds on the nose. He'll look to unify his belt with that of interim titleholder Justin Gaethje, who also weighed 155 pounds. Khabib was initially slated to fight Tony Ferguson at UFC 249 earlier this year, but the global coronavirus pandemic scuttled that fight. After Khabib was stuck in lockdown in Russia, Gaethje stepped in and defeated Ferguson for the interim belt at UFC 249 in May. The UFC 254 co-main event features former middleweight champion Robert Whittaker squaring off with rising contender Jared Cannonier, who is staring at a title shot against current champion Israel Adesanya with a win. Whittaker weighed in at 186 pounds for the fight, while Cannonier weighed 185 pounds. Two UFC 254 fighters miss weight Though Khabib and Gaethje made weight for their headlining bout, two other UFC 254 fighters missed the mark. Alex Oliveira weighed 173 pounds for his preliminary welterweight bout opposite Shavkat Rakhmonov, who weighed 171 pounds. Oliveira was 2 pounds over the limit for the non-title fight. Oliveira will forfeit a portion of his fight purse to keep the bout on the fight card. Joel Alvarez, who is slated to open the UFC 254 prelims, missed weight by 3.5 pounds. Alvarez weighed in early during the two-hour window. He will forfeit a portion of his fight purse in order to keep the fight with Alexander Yakovlev intact. Yakovlev weighed 155.5 pounds. Several UFC 254 alternate fighters make weight There were several alternate fighters that made weight ahead of Saturday's bouts. It was widely known that former Bellator lightweight champion Michael Chandler was inked to be the back-up in case either Khabib or Gaethje couldn't make it to the cage, which now seems unlikely. Chandler stepped on the scale at 155 pounds. Sergey Morozov was initially slated to fight Umar Nurmagomedov at UFC 254, but Nurmagomedov was forced out of the fight with a staph infection. Morozov was on hand and made weight as a back-up for the 140-pound catchweight bout between Casey Kenney and Nathaniel Wood. Kenney and Wood both made weight. Whittaker teammate Isi Fitikefu also weighed in as an alternate at 203.5 pounds. According to MMA Fighting, one of Ion Cutelaba's cornermen tested positive for COVID-19, so Fitikefu weighed in as a back-up to the UFC 254 main card opener between Magomed Ankalaev and Cutelaba, who both made weight as well. NOTE: UFC 254 has a special Main Card start time of 2 pm ET / 11 am PT with the Prelims beginning at 11 am ET / 8 am PT. TRENDING > Dana White: Khabib vs. Gaethje trending to be biggest UFC event ever UFC 254: Khabib vs. Gaethje weigh-in results UFC 254 Main card (2 p.m. ET on ESPN+ PPV) Khabib Nurmagomedov (155) vs. Justin Gaethje (155)Michael Chandler (155) – UFC 254 main event back-up fighterRobert Whittaker (186) vs. Jared Cannonier (185)Alexander Volkov (265) vs. Walt Harris (254)Jacob Malkoun (186) vs. Phil Hawes (186)Lauren Murphy (126) vs. Liliya Shakirova (126)Magomed Ankalaev (205.5) vs. Ion Cutelaba (205.5)Isi Fitikefu (203.5) – light heavyweight back-up fighter UFC 254 Prelims (12 p.m. ET on ESPN+, ESPN2) Stefan Struve (265) vs. Tai Tuivasa (265)Nathaniel Wood (140) vs. Casey Kenney (140)Sergey Morozov (139.5) – catchweight bout back-up fighterAlex Oliveira (173)* vs. Shavkat Rakhmonov (171)Da Un Jung (206) vs. Sam Alvey (206) UFC 254 Early Prelims (11 a.m. ET on ESPN+) Liana Jojua (126) vs. Miranda Maverick (126)Joel Alvarez (159.5)** vs. Alexander Yakovlev (155.5) *Oliveira missed weight by 2 pounds.** Alvarez missed weight by 3.5 pounds. Trending Video > Khabib Nurmagomeodv and Justin Gaethje weigh-in (Video courtesy of ESPN MMA)
Mitsubishi Chemical Holdings Corporation announced changing of representative corporate executive officers.
Global stocks barely budged on Friday as investors tightened positions with less than two weeks to go before the U.S. presidential election and awaited a breakthrough in stimulus talks in Washington. The final debate between U.S. President Donald Trump and his Democrat challenger Joe Biden on Thursday presented few surprises for election watchers but slightly reinforced investor caution heading into the Nov. 3 poll.
Cell Sorting Market Research Report by Technology (Fluorescence-Based Droplet Cell Sorting, Magnetic-Activated Cell Sorting (MACS), and Micro-Electromechanical System (MEMS)), by Offering (Cell Sorters, Cell Sorting Reagents & Consumables, and Cell Sorting Services), by Application, by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19New York, Oct. 23, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Cell Sorting Market Research Report by Technology, by Offering, by Application, by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p05913779/?utm_source=GNW The Global Cell Sorting Market is expected to grow from USD 223.12 Million in 2019 to USD 331.32 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 6.81%. Market Segmentation & Coverage: This research report categorizes the Cell Sorting to forecast the revenues and analyze the trends in each of the following sub-markets: Based on Technology, the Cell Sorting Market studied across Fluorescence-Based Droplet Cell Sorting, Magnetic-Activated Cell Sorting (MACS), and Micro-Electromechanical System (MEMS). The Fluorescence-Based Droplet Cell Sorting further studied across Cuvette-Based Cell Sorting and Jet-In-Air Cell Sorting. Based on Offering, the Cell Sorting Market studied across Cell Sorters, Cell Sorting Reagents & Consumables, and Cell Sorting Services. Based on Application, the Cell Sorting Market studied across Clinical and Research. The Research further studied across Drug Discovery, Immunology & Cancer Research, and Stem Cell Research. Based on End User , the Cell Sorting Market studied across Hospitals and Clinical Testing Laboratories, Medical Schools and Academic Institutions, Pharmaceutical and Biotechnology Companies, and Research Institutions. Based on Geography, the Cell Sorting Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom. Company Usability Profiles: The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Cell Sorting Market including Affymetrix, Inc., Beckman Coulter, Inc., Becton, Dickinson, and Company, Bio-Rad Laboratories, Inc., Cytonome/St, LLC, Miltenyi Biotec GmbH, On-Chip Biotechnologies Co., Ltd., Sony Biotechnology Inc., Sysmex Partec GmbH, and Union Biometrica, Inc.. FPNV Positioning Matrix: The FPNV Positioning Matrix evaluates and categorizes the vendors in the Cell Sorting Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape. Competitive Strategic Window: The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth. Cumulative Impact of COVID-19: COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market. The report provides insights on the following pointers: 1\. Market Penetration: Provides comprehensive information on the market offered by the key players 2\. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets 3\. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments 4\. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players 5\. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments The report answers questions such as: 1\. What is the market size and forecast of the Global Cell Sorting Market? 2\. What are the inhibiting factors and impact of COVID-19 shaping the Global Cell Sorting Market during the forecast period? 3\. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cell Sorting Market? 4\. What is the competitive strategic window for opportunities in the Global Cell Sorting Market? 5\. What are the technology trends and regulatory frameworks in the Global Cell Sorting Market? 6\. What are the modes and strategic moves considered suitable for entering the Global Cell Sorting Market? Read the full report: https://www.reportlinker.com/p05913779/?utm_source=GNW About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ CONTACT: Clare: email@example.com US: (339)-368-6001 Intl: +1 339-368-6001
Mohamed Fathi, coach of Mosul's football club in northern Iraq, hardly recognises the ruined soccer stadium once used by Islamic State group fighters to fire rockets and lob mortars from.
(Bloomberg) -- The Riksbank governor, Stefan Ingves, fears the economic outlook is deteriorating amid signs the coronavirus pandemic is tightening its grip across Europe, and ensnaring Sweden again too.“If you look at our forecasts, it will take a few years before GDP is back” at pre-crisis levels, Ingves said in an interview in Stockholm. “And those forecasts were done before the rather bleak situation that we are seeing in Europe today, so there’s reason to believe that the risks at the moment are skewed more to the downside.”Sweden has stood out for its hands-off strategy in tackling the Covid crisis. The country suffered a higher death rate than many other places in Europe, but had seemed a likely candidate for herd immunity. What’s more, its decision to avoid a lockdown appeared to shield the Swedish economy. However, recent figures show it hasn’t escaped the second wave of infections engulfing the rest of the region.The Riksbank’s latest economic forecasts for Sweden, published on Sept. 22, point to a 3.6% GDP drop this year, less than half the contraction predicted for the euro zone by the European Central Bank. The Riksbank kept its main interest rate at zero last month, and Ingves wants to rely more on asset purchases than rate cuts to support the economy.“Buying 45% of the outstanding stock of government bonds hasn’t been a problem,” the governor said, adding that the Riksbank “can buy a lot more” covered bonds, “and the same thing goes for municipal bonds.”Asked about the Riksbank’s decision to include corporate bonds in its purchases, Ingves said the size of the program means “there’s a lot of room left.”The corporate-bond program, launched this year after Sweden’s credit market temporarily froze, has drawn criticism from institutional investors who say the intervention is untimely and bad for pricing. Ingves has argued that the bank needs to expand its toolbox so that it’s prepared to act in case there’s another bout of market turmoil.But monetary policy shouldn’t be the only support mechanism, according to the governor.“We expect expansionary fiscal policy this year and next, which is reasonable given the circumstances,” he said. “Fiscal policy can assist with general demand, and the higher the demand is, the more likely it is that inflation will also rise. But the aim of fiscal policy is not to bring up inflation. That is our job.”What Bloomberg’s Economists Say...“Our high-frequency, activity tracker through Oct. 20 shows Swedish activity has slowed compared with other advanced economies in the past few weeks” -Johanna Jeansson. Read her SWEDEN INSIGHTDespite years of historically low interest rates, the Riksbank has failed to restore price growth to its 2% target. The inflation rate followed by the Riksbank was just 0.3% in September. Last week, Danske Bank’s chief economist said the central bank appears to have run out of options to revive inflation.“We have to live with the fact that it will take a couple of years before the inflation rate approaches 2% again,” Ingves said.(Updates with chart showing Covid-19 cases in Nordic countries)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Press release Hørsholm, Denmark (23 October 2020) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced several updates related to its planned filing of a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) for dovitinib, a pan-tyrosine kinase inhibitor (TKI) that is one of Allarity’s priority programs.The Company is announcing an update on timing for its originally planned first NDA filing for dovitinib as a treatment for renal cell carcinoma (RCC). This NDA is based on non-inferiority to the approved drug sorafenib. The Company’s preparation of the application itself is progressing as scheduled, however the third-party contract manufacturer of the registration batch of the drug is experiencing delays, in part as a result of the ongoing coronavirus pandemic. A registration batch is a mandatory component of the NDA filing. Due to this reported delay, Allarity is now expecting to file the NDA in 2021.Separately, the Company remains on track to file its first pre-market approval (PMA) application with the U.S. FDA for the use of the dovitinib DRP® companion diagnostic to select and treat likely responders to the drug. If regulatory authorities provide the expected PMA approval of the Dovitinib DRP® and an NDA approval of dovitinib, the Company believes it can make the drug available to DRP®-selected RCC patients as an effective new therapy to treat their disease. Dovitinib, originally developed by Novartis, addresses a significant unmet need for improved therapies for the treatment of RCC, and is a potential therapeutic alternative to sorafenib. Annual sales of sorafenib, under the trade name Nexavar®, were approximately USD $715 million in 2018. The global RCC market is projected to grow to USD $6.3 billon by 2022. In addition to the RCC market, dovitinib has promising potential as a monotherapy in a number of other indications, including estrogen receptor (ER) positive metastatic breast cancer, hepatocellular cancer, endometrial cancer and gastrointestinal stromal tumors, as well as in combination therapy with other approved drugs, including immune checkpoint inhibitors.Steve Carchedi, CEO of the Company, noted “Although we are disappointed with the unanticipated contract manufacturing delay for our priority dovitinib program, and the resulting setback of our planned first NDA filing for this promising cancer therapeutic, we recognize the delays are a result of the ongoing coronavirus pandemic that is affecting many facets of our industry. We remain fully committed to advancing the near-term filing of our first dovitinib NDA towards hopeful U.S. approval and to bringing this beneficial cancer therapeutic to RCC patients. Moreover, we are enthusiastic about remaining on track with our planned PMA filing for the Dovitinib DRP® companion diagnostic this year.” About Allarity Therapeutics Allarity Therapeutics (Nasdaq First North Growth Market Stockholm: ALLR.ST) develops drugs for personalized treatment of cancer guided by its proprietary drug response predictor technology, the DRP® platform. The company has a mature portfolio of six drug candidates, including compounds in the pre-registration stage. The product portfolio includes: stenoparib (2X-121), a PARP inhibitor in Phase 2 for ovarian cancer; dovitinib, a pan-TKI in post-Phase 3 for renal cell carcinoma; IXEMPRA® (Ixabepilone), a microtubulin inhibitor approved in the U.S. for the treatment of breast cancer; LiPlaCis®, a liposomal formulation of cisplatin in Phase 2 trials for breast and prostate cancer; 2X-111, a liposomal formulation of doxorubicin under manufacturing for Phase 2 in breast cancer; and irofulven, a DNA damaging agent in Phase 2 for prostate cancer.About the Drug Response Predictor – DRP® Companion Diagnostic Allarity uses its drug specific DRP® to select those patients who, by the genetic signature of their cancer, are found to have a high likelihood of responding to the specific drug. By screening patients before treatment, the response rate can be significantly increased. The DRP® method builds on the comparison of sensitive vs. resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology and prior clinical trial outcomes. DRP® is based on messenger RNA from the patient’s biopsies. DRP® has proven its ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients in nearly 40 clinical studies that were examined, including an ongoing, prospective Phase 2 trial. The DRP® platform can be used in all cancer types and is patented for more than 70 anti-cancer drugs.Follow us on social media: Facebook: https://www.facebook.com/AllarityTx/ LinkedIn: https://www.linkedin.com/company/allarity/ Twitter: https://twitter.com/allaritytxForward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of Allarity’s control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning Allarity’s plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. Allarity undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.Media Contacts:Europe: Thomas Pedersen Carrotize PR & Communications +45 6062 9390 firstname.lastname@example.orgU.S. Mike Beyer Sam Brown Inc. +1 312-961-2502 email@example.comCertified Adviser: Svensk Kapitalmarknadsgranskning AB, Email: firstname.lastname@example.org. Tel: +46 11 32 30 732This information is information that Allarity A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication on 23 October 2020. Attachment * Dovitinib Program Updates_Oct 2020
Barclays beat forecasts on income, profits, and loss provisions in the third quarter.
Who won the final presidential debate? We asked those who attended a drive-in viewing party in San Francisco, and got a wide range of responses.
China's solar industry is expected to embrace faster growth against the background that China aims to have CO2 emissions peak before 2030 and achieve carbon neutrality before 2060, according to experts at a photovoltaic conference held on Thursday in Jintan, Jiangsu Province, China.
Australian police said on Friday they charged 44 men with possessing and producing child-abuse material after a year-long investigation into dissemination of abhorrent content on the internet. Police also removed 16 children from harm in an operation that saw arrests in almost all of the country's eight states and territories, the Australian Federal Police (AFP) said in a statement. The AFP said it began the investigation after receiving a report that thousands of people were using an unspecified cloud storage platform to spread child-abuse material.
The amount of retail sales saw a 1.5% rise last month, boosted by DIY and garden items.
A few days before the long-awaited start of the Big Ten football season, Ohio State coach Ryan Day was not about to celebrate a win over COVID-19. Coronavirus outbreaks at Baylor, Memphis, Arkansas State, Notre Dame, Florida and elsewhere have forced programs to shut down for as much as two weeks. On the other side of an outbreak, though, things can be less stressful for teams and their coaches.
Beginning Monday, youth dance classes at City Ballet San Francisco will have to move online or outdoors, as ordered by the City Attorney's Office.
Even the president said he respected Welker’s handling of the debate
The Global Shot Peening Machines Market will grow by $ 32.33 mn during 2020-2024
China's top leaders will chart the country's economic course for 2021-2025 at a key meeting starting on Monday, seeking to balance growth and reforms to avoid stagnation amid an uncertain global outlook and deepening tensions with the United States. President Xi Jinping and members of the Central Committee, the largest of the ruling Communist Party's elite decision-making bodies, will meet on Oct. 26-29 behind closed doors to lay out the 14th five-year plan, a blueprint for economic and social development. The plan and its execution will be crucial for China to avoid the so-called "middle income" trap, policy insiders say, referring to the struggle of many economies to boost productivity and shift towards higher value-added industries.
Muhammad Ikram, 32, takes aim, flexes his neck and strikes with his chin, sending the cue ball across the table and sinking his shot in a corner pocket. Born without arms, Ikram has nevertheless mastered the game of snooker. In Samundri, a dusty, rural town in Punjab province, Ikram has spent eight years pushing a cue ball around with his chin, and now he can take on anyone.
For 9 months of 2020, the unaudited consolidated net profit of the AB INVL Baltic Farmland group was EUR 267 thousand and the revenue was EUR 460 thousand (for 9 months of 2019 consolidated net profit was EUR 247 thousand, revenue was EUR 453 thousand).Additional information: INVL Baltic Farmland, a company that invests in agricultural land, had revenue of EUR 460 thousand and a net profit of EUR 267 thousand in the first three quarters of this year. Compared to the same period last year, the company’s revenue grew 1.5%, while its net profit increased 8.1%.The company’s equity at the end of September this year was EUR 13.387 million, or EUR 4.15 per share. Equity per share increased 9.25% from a year earlier, also accounting for dividends that were paid out.“Favourable weather conditions in 2020 led to a bigger grain harvest in Lithuania, so there’s dominant mood of optimism in the agricultural sector. We for our part view the situation in agriculture as stable and continue seeking to ensure the effective management of assets,” said Justė Gumovskienė, the director of INVL Farmland Management, which is the administrator of INVL Baltic Farmland’s land.According to the operating forecasts for this year, INVL Baltic Farmland plans to get revenue of EUR 652 thousand and earn a consolidated net profit of EUR 390 thousand. The company’s revenue in the first three quarters of the year was 70.6% of the full-year forecast, while its net profit was 68.5% of the amount forecast for the year. Excluding the effect of provisions for receivables in the reporting period, the net profit figure would be 77.7% of the full-year forecast.The operating forecasts assume that during this year the value of the company’s land holdings will not change, there will be no land purchase or sale transactions, and there will be no changes in provisions for receivable amounts or impact of tenant debts on the size of the administration fee.INVL Baltic Farmland is listed on the Nasdaq Vilnius stock exchange. Its subsidiaries own nearly 3 thousand hectares of agricultural land in Lithuania which is rented out to agriculture companies and farmers.The person authorized to provide additional information: Director Egle Surpliene E-mail: email@example.comAttachment * Factsheet_2020 3Q_INVL Baltic Farmland